Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians.

Background Limited treatment information is available when patients present with psychotic symptoms secondary to synthetic cannabinoid (SC) use. Symptoms associated with use are often indistinguishable from those encountered with a primary mental illness and also include aggression, confusion, and anxiety. For these patients, clinicians rely on physical presentation, symptom(s) onset, and episode duration when evaluating patients. Patient History An adult man was involuntarily admitted to inpatient status secondary to reports of bizarre behaviors that included paranoia and psychomotor agitation. Because of the severity of the symptoms, he was unable to participate in the admission assessment. On day 2, he reported having smoked a substance provided by a friend. In addition, he admitted to previous SC use on 3 occasions, with each occasion resulting in an involuntary admission to inpatient status. The course of this admission was unremarkable. Conclusions A brief overview of psychiatric signs and symptoms of SC use and information to help clinicians are included. The presentation of psychotic symptoms secondary to SC may be consistent with those of psychosis or other substances of abuse. Because of the variability in the symptoms produced by SC use, clinicians are encouraged to consider SC use in the diagnostic evaluation.

[1]  E. Delaney,et al.  International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids , 2016, Brain Research Bulletin.

[2]  L. Fattore Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis , 2016, Biological Psychiatry.

[3]  D. Castellanos,et al.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice. , 2016, World journal of clinical pediatrics.

[4]  T. M. Martin,et al.  Validation of an ELISA Synthetic Cannabinoids Urine Assay , 2015, Therapeutic drug monitoring.

[5]  Takeshi Saito,et al.  Comprehensive review of the detection methods for synthetic cannabinoids and cathinones , 2015, Forensic Toxicology.

[6]  D. Greydanus,et al.  Cannabis: a controversial 21st-century drug of antiquity. , 2014, Georgian medical news.

[7]  D. D’Souza,et al.  Spicing things up: synthetic cannabinoids , 2013, Psychopharmacology.

[8]  S. Sampson,et al.  Benzodiazepines for psychosis-induced aggression or agitation. , 2013, The Cochrane database of systematic reviews.

[9]  O. Freudenreich,et al.  How to Stabilize an Acutely Psychotic Patient: In Psychiatric Emergencies, Use a Stepwise Approach to Provide Safe, Effective Treatment , 2012 .

[10]  K. Heard,et al.  A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. , 2012, Annals of emergency medicine.

[11]  M. Forrester,et al.  Synthetic Cannabinoid Exposures Reported to Texas Poison Centers , 2011, Journal of addictive diseases.

[12]  Andrej Grigoryev,et al.  Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  T. Stern,et al.  The assessment and management of agitation and delirium in the general hospital. , 2010, Primary care companion to the Journal of clinical psychiatry.

[14]  G. Currier,et al.  Pharmacological Treatment of Psychotic Agitation , 2002, CNS drugs.

[15]  J. Levenson Neuroleptic malignant syndrome. , 2007, The American journal of psychiatry.